A Study of Cabergoline for the Treatment of Cocaine Dependence - 1
The purpose of this study is to assess cabergoline for the Treatment of Cocaine...
Brief Summary
Official Title: “Phase 2, Double-Blind, Placebo Controlled Trial of Cabergoline for the Treatment of Cocaine Dependence”
The purpose of this study is to assess cabergoline for the Treatment of Cocaine Dependence
- Study Type: Interventional
- Study Design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Detailed Clinical Trial Description
To assess the efficacy and safety of cabergoline in reducing cocaine use in subjects with cocaine dependence. This is a DB, placebo-controlled, parallel group design study where subjects will receive either .5mg cabergoline or placebo for 12 weeks with a 4 week follow-up.
Intervention(s) in this Clinical Trial
- Drug: Cabergoline
Outcome Measures for this Clinical Trial
Primary Measures
- New Use
- reduction of severity of cocaine dependence
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- Must have a DSM-4 criteria for cocaine dependence; be seeking treatment for cocaine dependence; have the ability to understand and provide written informed consent; females of child-bearing potential using proper method of birth control.
Exclusion Criteria:
- Additional criteria available during screening at the site.
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 18 Years
Maximum Age for this Clinical Trial: N/A
Are Healthy Volunteers Accepted for this Clinical Trial?: No
Clinical Trial Investigator Information
Lead Investigator: National Institute on Drug Abuse (NIDA) NIH
Overall Clinical Trial Officials and Contacts
Steve Shoptaw, Ph.D. Principal Investigator Friends Research Institute, Inc.
Additional Information
Information obtained from ClinicalTrials.gov on February 09, 2012
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00033111
Study ID Number: NIDA-CTO-0007-1
ClinicalTrials.gov Identifier: NCT00033111
Health Authority: United States: Food and Drug Administration
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
The URL of this page is:
http://clinicaltrialsfeeds.org/clinical-trials/show/NCT00033111
